PCOS Healthcare Trends · Trends and research
GLP-1 medicines and PCOS/PMOS: what patients are asking, what a new review found
Few topics now come up in PCOS/PMOS appointments as often as GLP-1 medicines. Patients are asking about them in clinics and in patient communities, clinics report the same rising volume of questions, and researchers are publishing reviews to map what has actually been studied. This piece does two things only: it reports that trend, and it walks through the newest map of the research — a scoping review published in September 2026 — in plain language, including the limits its own authors put up front. It makes no claim about whether any medicine is right for any person.
First, the trend itself — reported as a trend
When we say more patients are asking about GLP-1 medicines, we mean exactly that: the volume of questions has risen. A question trend tells you what people want to understand. It does not tell you whether a medicine works, for whom, or at what risk — those are research and clinical questions, and they are the rest of this page. Our glossary covers the surrounding terms — insulin resistance, androgens, and metabolic syndrome — in plain language, and our explainer on insulin resistance in PCOS/PMOS explains why metabolic topics sit at the centre of so many of these conversations.
What “GLP-1 medicine” means, in one paragraph
GLP-1 is short for glucagon-like peptide-1, a hormone signal the gut releases after eating that is involved in insulin release and appetite signalling. Medicines in this class — called GLP-1 receptor agonists — are designed to act on that same signal. They were developed for diabetes and weight-related care in the general population. The 2023 International Evidence-based Guideline for PCOS/PMOS does not frame them as a treatment for the condition itself; as summarised below, it frames them as one option clinicians could consider for managing higher weight in adults with this condition, under general-population guidance.
The new map: a scoping review of 28 studies
In September 2026, researchers at Nova Southeastern University published a scoping review in Cureus on the reproductive and gynaecologic side of this literature. A scoping review is a map, not a verdict: its job is to gather what exists and describe its shape, not to pool results into one bottom-line number. The authors searched four databases, screened 1,416 records, and included 28 studies of GLP-1 medicines in women with PCOS/PMOS that reported reproductive or gynaecologic outcomes.
What the map shows about the shape of the research:
- The older medicines carry most of the evidence. Liraglutide was the most studied medicine in the review (15 studies), followed by exenatide (five) and semaglutide (four). The medicines patients ask about most today are not necessarily the ones with the most PCOS-specific research behind them.
- Androgen markers were the most consistently reported outcome. The review reported that, across the included studies, changes in biochemical markers of androgen excess — such as total and free testosterone and androstenedione, alongside rises in SHBG, the protein that keeps some androgen inactive — were described more consistently than other reproductive outcomes.
- Menstrual regularity was frequently reported. The review noted that improvements in menstrual regularity and reductions in absent periods were also frequently reported in the included studies.
- Fertility and pregnancy outcomes were the thinnest part. The authors described the evidence on ovulation, fertility, and pregnancy as more limited, with some reports in selected groups — often where a GLP-1 medicine was combined with metformin — and they were explicit that this part of the literature is comparatively small.
- The studies were too different to pool. The review reported considerable differences in study design, medicines, and outcomes measured, which is why its authors did not combine the results into a single quantitative estimate.
Those are the review’s descriptions of its included studies, reported here as the authors presented them. A scoping review, by its own design, does not grade how strong each study was — and this page does not upgrade its map into a promise.
What the authors themselves flagged as unknown
- Direct effect, or a follow-on from weight and metabolic change? Coverage and discussion of the review return to the same open question its field has not settled: when reproductive changes were reported, it remains unclear whether they reflect a direct effect of the medicine or an indirect one that follows weight change and improved metabolic markers. The review does not answer that question, and neither can this page.
- Pregnancy safety has not been established. The review did not establish safety in pregnancy. The 2023 guideline, in its discussion of this medicine class, advises clinicians to ensure effective contraception when pregnancy is possible while these medicines are used, because pregnancy safety data are lacking — and guidance discussed in the literature is to stop these medicines before a planned conception. Timing and planning belong in a direct conversation with your own clinician, well before conception is attempted.
- How long, and what happens after stopping? A second review, published online on November 10, 2026 in Expert Opinion on Pharmacotherapy, looked at the newer generation of incretin medicines — from single GLP-1 medicines to dual and triple-signal medicines now in the pipeline. Its authors reached a similar caution in their own words: whether any reproductive change is independent of weight change, whether it persists after treatment is stopped, and whether it differs across the different presentations of this condition are all still uncertain, and they called for trials designed around those differences, with standardised reproductive, metabolic, and safety measures.
What the guideline actually says — and does not say
The 2023 International Evidence-based Guideline — the reference clinicians are pointed to for this condition, maintained by the program at Monash University — says, in its own wording as widely summarised, that anti-obesity medicines including liraglutide and semaglutide “could be considered, in addition to active lifestyle intervention, for the management of higher weight in adults with PCOS as per general population guidelines.” Three parts of that sentence matter:
- “Could be considered” is deliberately cautious language — an option to discuss, not a recommendation for any individual.
- “For the management of higher weight” names the purpose the guideline attaches to these medicines. It does not describe them as treating the underlying condition.
- “As per general population guidelines” means eligibility and follow-up follow the same rules used outside PCOS/PMOS care — there is no separate PCOS-specific pathway in the guideline for this class.
The guideline framing also leaves out an important group by design: it is about adults with higher weight. It says nothing that turns these medicines into a topic for every patient — including lean patients, for whom weight is not part of their picture and whose questions are usually about cycles, skin and hair, fertility timing, and metabolic screening instead.
What this does not mean
- A rising number of questions is not evidence that a medicine works for this condition, or for you.
- A review that maps 28 studies is not the same as 28 strong studies — the review’s own authors noted how varied the designs and outcomes were.
- Nothing in either review, and nothing on this page, is a recommendation to start, stop, or change any medicine — and this directory endorses no medicine, product, or provider.
- If fertility is part of your near-term plans, the pregnancy-safety gap above is the single most important paragraph on this page to discuss with your clinician, before anything else.
Which clinician handles which part of this conversation
- Primary care and OB-GYN clinicians are often the first stop: they hold the whole picture — cycles, metabolic screening, and what else is already being tried — and can say whether a weight-management conversation is even relevant in your case.
- Endocrinologists focus on hormone and metabolic questions, which is where most detailed discussions of this medicine class take place when one is had.
- Reproductive endocrinologists are the right stop when fertility timing is central, including how any medicine plan fits around conception planning.
- Registered dietitians work on the food and day-to-day side that the guideline pairs with any medicine discussion — the “in addition to active lifestyle intervention” part, in practice.
What this means when you are finding care
A provider page that discusses metabolic health, weight, and screening in the measured terms the guideline uses — an option to consider, with open questions named — is describing this topic the way the current literature does. You can search the directory for PCOS/PMOS-focused providers, browse by state — for example, the Florida listings page — and use the plain-language glossary before a visit.
Questions worth asking your provider
- Is a weight-management conversation relevant in my case at all — or are my priorities cycles, skin and hair, fertility, or screening?
- If we discuss this medicine class, are we discussing it for weight management under general-population guidance, as the guideline frames it?
- What do we not yet know — including whether any reported change is direct or follows weight change?
- How does conception planning fit with any medicine we discuss, and what would need to stop, and when, if my plans change?
- What follow-up and screening would continue either way — glucose, lipids, blood pressure, and cycle tracking?
- Who on my care team would follow this over time, so the plan does not sit with no owner?
Sources
- Snytte J, Hazan B, Weissman A, Mayrovitz HN. Reproductive and Gynecologic Effects of Glucagon-Like Peptide-1 Receptor Agonists in Women With Polycystic Ovary Syndrome: A Scoping Review. Cureus, September 28, 2026 — doi.org/10.7759/cureus.117072 (PubMed record: PMID 42953685)
- Saydam BO, Yildiz BO. Next-generation incretin therapeutics for polyendocrine metabolic ovarian syndrome: navigating current pipeline and clinical considerations. Expert Opinion on Pharmacotherapy, published online November 10, 2026 — PubMed record, PMID 42978208
- Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, Journal of Clinical Endocrinology & Metabolism, 2023 — read the guideline (PMC)
- The guideline program’s home at Monash University — Monash Centre for Health Research and Implementation — PCOS
- Coverage of the Cureus review — News-Medical — could GLP-1 drugs help beyond weight loss?
Looking for care? Find a PCOS/PMOS-focused provider or browse by state.
This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.